Introduction: Liquid biopsy, especially when performed by the isolation, expansion, and examination of circulating tumor cells (CTCs) from peripheral blood, has become an innovative and transforming diagnostic tool in Clinical Oncology. The CTCs have already entered the clinical practice as an alternative method to invasive tumor biopsy for detecting postsurgical and/or posttreatment minimal residual disease, to predict cancer recurrence and real-time treatment response. In this context, the retrospective observational project, known as CHARACTEX, has permitted to state that it is possible to exploit blood-based cytologic samples through short-term culture and in vitro CTC expansion. Methods: This method is based initially on a gradient-sedimentation technique, which impoverishes without completely depriving the obtained sample from the hematological cells, followed by short-term (14 days) in vitro culture and expansion and cytomorphological and flow cytometric analysis to investigate whether the expanded cell population possesses proliferative advantage and fits with criteria, which are consistent to the known primary tumor. Results: The originality of this method is that, apart from the above exposed criteria, there is no selection bias for the isolation of the cells from peripheral blood (like immunomagnetic bead treatment or preliminary immunocytochemistry), which can potentially introduce some limitation to the cell population under evaluation. Conclusion: The examination of the expanded cell population obtained by this method is very rewarding for both the pathologist – who can assess multiple tumor-related variables (like immunocytochemistry, flow cytometry of several parameters, and molecular pathology on cell suspensions and cell blocks obtained from them) – and the clinician.

Keywords:
Liquid biopsy, Circulating tumor cells, Cytology, Short-time culture, Molecular pathology, Predictive cancer tests
1.
Razavi P, Li BT, Hou C, Shen R, Venn O, Lim RS, et al. Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: implications for interpretation of liquid biopsy tests. J Clin Oncol. 2017 May;35(Suppl 15):11526.
2.
Malara N, Gentile F, Coppedè N, Coluccio ML, Candeloro P, Perozziello G, et al. Superhydrophobic lab-on-chip measures secretome protonation state and provides a personalized risk assessment of sporadic tumour. NPJ Precis Oncol. 2018;2(1):26.
3.
Coluccio ML, Gentile F, Presta I, Donato G, Coppedè N, Valprapuram I, et al. Tailoring chemometric models on blood-derived cultures secretome to assess personalized cancer risk score. Cancers. 2020;12(6):1362.
4.
Malara NM, Givigliano F, Trunzo V, Macrina L, Raso C, Amodio N, et al. In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients. J Biol Regul Homeost Agents. 2014;28(4):717–31.
5.
Malara N, Trunzo V, Foresta U, Amodio N, De Vitis S, Roveda L, et al. Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment. J Transl Med. 2016;14(1):133.
6.
Peralta M, Osmani N, Goetz JG. Circulating tumor cells: towards mechanical phenotyping of metastasis. iScience. 2022;25(3):103969.
7.
Xiang Z, Zhou ZJ, Xia GK, Zhang XH, Wei ZW, Zhu JT, et al. A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. Oncogene. 2017;36:5122–33.
8.
Lanuti P, Simeone P, Rotta G, Almici C, Avvisati G, Azzaro R, et al. A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. Sci Rep. 2018;8(1):5823.
9.
Bordelon H, Russ PK, Wright DW, Haselton FR. A magnetic bead-based method for concentrating DNA from human urine for downstream detection. PLoS One. 2013;8(7):e68369.
10.
Perozziello G, Catalano R, Francardi M, Rondanina E, Pardeo F, Angelis FD, et al. A microfluidic device integrating plasmonic nanodevices for Raman spectroscopy analysis on trapped single living cells. Microelectronic Engineering. 2013;111:314–9.
11.
Jahr S, Hentze H, Englisch S, Hardt D, Fa- ckelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001 Feb;61(4):1659–65.
12.
Volpentesta G, Donato G, Ferraro E, Mignogna C, Radaelli R, Sabatini U. Pilocytic astrocytoma-derived cells in peripheral blood: a case report. Front Oncol. 2021;2711:737730.
13.
Malara N, Guzzi G, Mignogna C, Trunzo V, Camastra C, Torre AD, et al. Non-invasive real-time biopsy of intracranial lesions using short time expanded circulating tumor cells on glass slide: report of two cases. BMC Neurol. 2016;16(1):127.
14.
Imamura F, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, et al. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer. 2016;94:68–73.
15.
Xia Y, Huang CC, Dittmar R, Du M, Wang Y, Liu H, et al. Copy number variations in urine cell-free DNA as biomarkers in advanced prostate cancer. Oncotarget. 2016;7(24):35818–31.
16.
Perdomo S, Avogbe PH, Foll M, Abedi-Ar- dekani B, Facciolla VL, Anantharaman D, et al. Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. Oncotarget. 2017;8(42):72621–32.
17.
Lianidou E, Alix-Panabières C. Early detection of lung cancer based on DNA methylation analysis in sputum and plasma. Transl Cancer Res. 2017 6 S1;6:S51–S53.
18.
Romano G, Mancini R, Fedele P, Curigliano G, Flamini G, Giovagnoli MR, et al. Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers. Anticancer Res. 1997 Jul-Aug;17(4A):2827–30.
19.
Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time? Cancer Letters. 2020;468:59–71.
20.
Innaro N, Gervasi R, Ferrazzo T, Garo NC, Curto LS, Lavecchia A, et al. Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell-based cytology. Cancer Med. 2022:1–8.
21.
Sakaeda S, Naito Y. Circulating tumor DNA in oncology. Processes. 2021;9(12):2198.
22.
Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointes-tinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26(12):1859–64.
23.
Malara NM, Leotta A, Sidoti A, Lio S, D'Angelo R, Caparello B, et al. Ageing, hormonal behaviour and cyclin D1 in ductal breast carcinomas. The Breast. 2006 Feb;15(1):81–9.
24.
Di Vito A, Giudice A, Chiarella E, Malara N, Bennardo F, Fortunato L. In vitro long-term expansion and high osteogenic potential of periodontal ligament stem cells: more than a mirage. Cell Transplant. 2019 Jan;28(1):129–39.
25.
Limongi T, Schipani R, Di Vito A, Giugni A, Francardi M, Torre B, et al. Photolithography and micromolding techniques for the realization of 3D polycaprolactone scaffolds for tissue engineering applications. Microelectronic Engineering. 2015;141:135–9.
© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.